Supplementary Figure 2 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis | Synapse
July 15, 2025
Supplementary Figure 2 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis
Key Points
Eltanexor effectively reduces xpo1 protein expression in various colorectal cancer cell lines.
Treatment prevents colony formation, indicating a decrease in tumorigenesis.
The study focuses on the modulation of the wnt/β-catenin signaling pathway by eltanexor.
These findings could improve therapeutic strategies for managing colorectal cancer.
Abstract
Figure S2. Eltanexor treatment reduces XPO1 protein expression in multiple CRC cell lines and prevents colony formation.